{"id":"W2886242456","doi":"10.1158/1557-3265.ovca17-pr06","title":"Abstract PR06: ARIEL3: A phase 3, randomized, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian cancer (OC)","year":2018,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; Ottawa Hospital; University Health Network","funders":"","keywords":"Medicine; BRCA mutation; Internal medicine; PARP inhibitor; Clinical endpoint; Oncology; Placebo; Population; Cancer; Ovarian cancer; Clinical trial; Pathology; Biology; Genetics; Poly ADP ribose polymerase","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002606051,0.002094422,0.003531028,0.0005763914,0.0006387914,0.001205812,0.001509033,0.00257153,0.009001961],"category_scores_gemma":[0.001761241,0.0008360991,0.001902374,0.0005445362,0.001447349,0.001200826,0.000419956,0.004999945,0.002010431],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007824453,"about_ca_system_score_gemma":0.001791123,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009131003,"about_ca_topic_score_gemma":0.002087663,"domain_scores_codex":[0.9991714,0.0004316339,0.00005319184,0.0001558391,0.0000611214,0.0001268801],"domain_scores_gemma":[0.9987478,0.0003284219,0.0002687512,0.0001025001,0.00008388166,0.0004686179],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9750208,0.01159577,0.0001798916,0.0003373805,0.0003801482,0.00002052334,0.00002468369,0.0001710015,0.003067743,0.00006395573,0.0006825876,0.008455516],"study_design_scores_gemma":[0.9106979,0.08746122,0.0006930176,0.0000131206,0.0001574466,0.00001698247,0.000007318816,0.0002837485,0.0003107618,0.0000679488,0.0002808206,0.000009756371],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9755151,0.004460574,0.00144902,0.0008498204,0.0008250795,0.01041544,0.00283117,0.0005683354,0.0030855],"genre_scores_gemma":[0.9740824,0.001968587,0.003189321,0.001893174,0.0006662169,0.01139713,0.001764255,0.00007157596,0.004967369],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.009001961,"threshold_uncertainty_score":0.03011459,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.3540392569924878,"score_gpt":0.5998549478083863,"score_spread":0.2458156908158985,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}